M Zubair Jafar, MD
Interventional Cardiology · Poughkeepsie, NYNPI 1790758688
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,600 of the $23,849 with a category attached, or 61.2%. 21 manufacturers reported payments, led by Johnson & Johnson at 40.9% of the total. Reporting peaked in 2019 at $17,751 and has fallen 80.0% since, to $3,553 in 2025.
Across 263 payments — averaging $90.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$10K
- Medtronic$7K
- Edwards Lifesciences$4K
- Abiomed$782
- Novartis$406
- Abbott$333
- plus $1K from 15 others
Across 48 payments — averaging $12,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$500K
- Medtronic$117K
- Novartis$7K
What the payments were for
- Speaking & faculty fees$14,60061%
- Travel & lodging$2,83312%
- Food & beverage$6,40727%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $9,764 |
| Medtronic(2 entities) | 95 | $6,663 |
| Edwards Lifesciences | 31 | $4,463 |
| Abiomed | 33 | $782 |
| Novartis | 23 | $406 |
| Abbott | 9 | $333 |
| Amgen | 16 | $309 |
| Shockwave Medical, Inc | 6 | $306 |
| Boston Scientific | 8 | $212 |
| Cardiovascular Systems Inc. | 5 | $157 |
| AstraZeneca | 10 | $135 |
| Inari Medical, Inc. | 2 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $55 |
| Pfizer | 4 | $54 |
| Biosense Webster, Inc. | 1 | $31 |
| Boehringer Ingelheim | 2 | $24 |
| Cardiva Medical, Inc. | 1 | $24 |
| Teleflex LLC | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$9,634
- CoreValve Evolut$4,926
- EVOQUE$2,030
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,500
How this compares
$23,849 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $200,165 |
| EntrestoSacubitril/Valsartan | 39 | $57,393 |
| XareltoRivaroxaban | 30 | $47,602 |
| Repatha SureclickEvolocumab | 58 | $46,221 |
| BrilintaTicagrelor | 37 | $39,975 |
| Repatha PushtronexEvolocumab | 40 | $38,420 |
| Praluent PenAlirocumab | 18 | $10,543 |
| VascepaIcosapent Ethyl | 16 | $7,916 |
| Atorvastatin Calcium | 410 | $6,383 |
| Ranolazine ErRanolazine | 36 | $6,163 |
| Repatha SyringeEvolocumab | 11 | $5,919 |
| Valsartan | 111 | $3,313 |
| Ezetimibe | 78 | $3,204 |
| Metoprolol Succinate | 164 | $2,572 |
| Rosuvastatin Calcium | 123 | $2,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $200,165141 claims |
| NovartisEntresto | $406 | $57,39339 claims |
| Johnson & JohnsonXarelto | $9,764 | $47,60230 claims |
| AstraZenecaBrilinta | $135 | $39,97537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Poughkeepsie
- Rajeev NarayanPoughkeepsie$116K
- Louis KantarosPoughkeepsie$65K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.